2017 Volume 127 Issue 8 Pages 1775-1779
Biological therapy has established the efficacy and safety profile for psoriasis treatment. The possible development of tuberculosis is one of the important issues during treatment, so an interferon-γ releasing assay (IGRA) such as QFT or T-spot is generally used to monitor tuberculosis in daily practice. We retrospectively investigated the clinical courses of QFT or T-spot testing in 386 patients with psoriasis during biologics treatments. Of these patients, 33 cases were positive in the IGRA assay, and 7 cases showed changes from positive to negative. These results suggest that IGRA assays can be affected by biological therapy.